Campagne de collecte 15 septembre 2024 – 1 octobre 2024 C'est quoi, la collecte de fonds?

Volume 47; Issue 1-supp-S1

Main
Urology
Volume 47; Issue 1-supp-S1

Urology

Volume 47; Issue 1-supp-S1

1

Introduction

Joseph E. Oesterling

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 218 KB

english, 1996

2

Hormone therapy for prostate cancer: a topical perspective

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 1.16 MB

english, 1996

3

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action

B.J.A. Furr, H. Tucker

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 1.46 MB

english, 1996

4

Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen

Louis Denis, C. Mahler

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 335 KB

english, 1996

5

Discussion session: The basic science of bicalutamide as a once-daily oral antiandrogen

S.Bruce Malkowicz

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 462 KB

english, 1996

6

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial

Mark S. Soloway, Paul F. Schellhammer, Joseph A. Smith, Gerald W. Chodak, Gerald T. Kennealey

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 617 KB

english, 1996

7

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

Gregory T. Bales, Gerald W. Chodak

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 611 KB

english, 1996

8

High-dose bicalutamide monotherapy for the treatment of prostate cancer

George R.P. Blackledge

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 493 KB

english, 1996

9

Discussion session: Clinical trials of bicalutamide as monotherapy for prostate cancer

Gerald L. Andriole

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 866 KB

english, 1996

10

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy

Paul Schellhammer, Roohollah Sharifi, Norman Block, Mark Soloway, Peter Venner, A.Lynn Patterson, Michael Sarosdy, Nicholas Vogelzang, Julie Jones, Geert Kolvenbag

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 840 KB

english, 1996

11

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

Howard I. Scher, Zuo Feng Zhang, David Nanus, William Kevin Kelly

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 1.10 MB

english, 1996

12

Worldwide activity and safety of bicalutamide: a summary review

Geert J.C.M. Kolvenbag, George R.P. Blackledge

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 1.23 MB

english, 1996

13

Discussion session: Clinical data on the role of bicalutamide in metastatic prostate cancer

Jerome P. Richie

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 568 KB

english, 1996

14

Defining the role of antiandrogens in the treatment of prostate cancer

David G. McLeod, Geert J.C.M. Kolvenbag

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 769 KB

english, 1996

15

Discussion session: The expected value of bicalutamide in the management of prostatic disease

Joseph E. Oesterling

Journal:

Année:

1996

Langue:

english

Fichier:

PDF, 929 KB

english, 1996